Maine Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

TL;DR

MaineCare (Maine Medicaid, administered by the Maine Department of Health and Human Services (DHHS) through a fee-for-service model with Change Healthcare Optum as PBM) does NOT cover GLP-1 receptor agonists for chronic weight management. The categorical exclusion is anchored in 10-144 C.M.R. ch. 101, Chapter II, § 80.06(A) (“Anorexic, or certain weight loss drugs”) and reaffirmed verbatim on the January 1, 2026 PDL: “Weight loss drugs are not covered as permitted by Federal Medicaid regulations and Maine Medicaid (MaineCare) Policy.”

Two narrow FDA-label-restricted carve-outs operate at the PDL coding level via PA Form #20420:

Architectural distinctive features:

• NO Wegovy MASH carve-out — the headline distinctive feature of this state. MaineCare's GI / NASH PDL category covers ONLY Rezdiffra (resmetirol). West Virginia, Arkansas, Oklahoma, Utah, and Nebraska all integrated Wegovy MASH after the August 2025 FDA-label expansion; Maine has not.
• BMI strictly > 27 for Wegovy CV — narrowest BMI threshold language. Most states accept BMI ≥ 27 (inclusive); Maine's strictly-greater-than language excludes patients at exactly 27.0 kg/m².
• T1DM AND T2DM both excluded from Zepbound OSA — verbatim “Not for patients with T1DM, T2DM.” Most state OSA carve-outs only exclude T1DM, routing T2D patients through standard step-therapy. Maine's dual-diabetes exclusion from OSA is structurally more restrictive than NE / WV / UT.
• HFrEF (EF < 45%) explicitly excluded from Wegovy CV — HFrEF patients are routed to SGLT2 (dapagliflozin / empagliflozin) instead of Wegovy, reflecting the CARDIAC RISK REDUCTION PDL category's structural separation between MACE-prevention (Wegovy / SELECT trial) and HFrEF-treatment (SGLT2 / DAPA-HF / EMPEROR-Reduced).
• FFS-dominant architecture — Maine does NOT operate full-risk Medicaid MCOs. The state Single PDL via Optum applies uniformly across the entire MaineCare population. PCCM / PCMH / health-home programs supplement FFS for primary-care coordination but do not affect pharmacy benefit administration. This contrasts with multi-MCO/multi-PBM states like Texas, Indiana, or Nebraska (three Heritage Health MCOs).
• 3-year sleep study window for OSA — longer than NE (24 months) and OK (12 months). Reduces re-testing burden but increases the diagnostic-decoupling risk where patient OSA severity may have changed since the most recent study.

The 2025 LD 480 cycle event: Representative Anne Graham (D-North Yarmouth) introduced LD 480 / HP 309 in the 132nd Maine Legislature, First Regular Session, on February 11, 2025. The bill would have mandated MaineCare reimbursement of FDA-approved GLP-1 receptor agonists for the treatment of obesity. The fiscal note projected approximately $42 million in FY26 and $53 million in FY27 in combined state-and-federal program cost. The bill was reported Ought-Not-To-Pass Pursuant To Joint Rule 310 on March 20, 2025, ending its progression for the session without a floor vote and reaffirming MaineCare's categorical chronic-weight-management exclusion through at least the 2025–2026 legislative cycle.

Medicaid expansion status: Maine voters approved Question 2 (the Medicaid expansion ballot initiative) in November 2017 with 59% support. After regulatory and operational delays under Governor Paul LePage, Medicaid expansion was implemented by Governor Janet Mills effective January 10, 2019 — making Maine the first state to expand Medicaid through a ballot initiative process. Total MaineCare enrollment is approximately 410,000 (one of the highest Medicaid penetration rates by share of state population in the United States, reflecting Maine's older and lower-income demographics).

Pharmacy benefit architecture:

• PBM: Change Healthcare Optum (Optum Rx)
• Provider PA helpdesk: 1-888-420-9711 or 1-888-445-0497 (email MaineHD@optum.com)
• Member helpdesk: 1-866-796-2463
• Single PDL: applies uniformly across FFS (no MCO formulary deviation — Maine has no full-risk Medicaid MCOs)
• PA Form: #20420 for both Wegovy CV and Zepbound OSA carve-outs

1. Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2)(A) grants states an optional authority to exclude “Agents when used for anorexia, weight loss, or weight gain” from coverage. Maine has exercised this authority — categorically — and has NOT executed a State Plan Amendment carve-back-in for chronic weight management. The two FDA-label-restricted carve-outs (Wegovy MACE and Zepbound OSA) operate at the PDL coding level via PA Form #20420, not at the State Plan Amendment level.

The MaineCare PDL effective January 1, 2026 reproduces the federal exclusion at the state PDL level. The verbatim Weight Loss section reads:

No longer covered: Phentermine, Xenical, Didrex, and Meridia. Weight loss drugs are not covered as permitted by Federal Medicaid regulations and Maine Medicaid (MaineCare) Policy.

This is the regulatory baseline against which the two FDA-label carve-outs operate as exceptions.

2. State anchor: 10-144 C.M.R. ch. 101, Ch. II, § 80.06(A)

The Code of Maine Rules at 10-144 C.M.R. ch. 101, Chapter II, Section 80.06 (“Drugs Not Covered”) anchors the MaineCare AOM exclusion as a binding state regulation. Verbatim:

A. Anorexic, or certain weight loss drugs.

...

N. Drugs, Medical Food or nutritional support products prescribed for managing body weight or enhancing nutritional intake when the member is able to eat conventional foods.

§ 80.06(A) covers the FDA-approved chronic weight management drug class (Wegovy, Zepbound, Saxenda, Foundayo, Contrave, Qsymia, Xenical, phentermine). § 80.06(N) extends the exclusion to medical foods and nutritional support products when the member can eat conventional foods.

This dual-layer (federal authority + state regulation) makes the categorical exclusion unappealable on regulatory grounds — appeals can only address whether the patient meets the criteria for one of the indication-restricted PDL carve-outs. Patients who qualify under Wegovy MACE or Zepbound OSA criteria do not face the § 80.06(A) exclusion because the FDA-label indications (cardiovascular risk reduction; moderate-to-severe OSA) are not categorized as “anorexic or weight loss” uses for PDL purposes.

3. Wegovy CV/MACE carve-out (CARDIAC RISK REDUCTION PDL category)

Per the MaineCare PDL effective January 1, 2026 CARDIAC RISK REDUCTION — SGLT2 / GLP-1 section, Wegovy is non-preferred and requires PA Form #20420. Criteria verbatim:

1. Patient does NOT have diagnosis of diabetes, end-stage renal disease/dialysis, or heart failure with reduced ejection fraction (HFrEF, EF < 45%).
2. Patient has BMI > 27 kg/m², AND is not being used for weight loss only.
3. Patient has history of at least one of the following:
   • Stroke
   • Myocardial infarction (MI)
   • Symptomatic peripheral arterial disease (PAD)

3.1 The HFrEF exclusion

MaineCare's Wegovy CV criteria explicitly exclude patients with heart failure with reduced ejection fraction (HFrEF, EF < 45%). This reflects the structural separation between MACE-prevention (Wegovy, based on the SELECT trial population of non-diabetic patients with established CVD) and HFrEF treatment (SGLT2 inhibitors, with dapagliflozin's DAPA-HF and empagliflozin's EMPEROR-Reduced trials establishing the FDA HFrEF indication for those drugs).

HFrEF patients with established CVD events are routed to the SGLT2 pathway under the same CARDIAC RISK REDUCTION PDL category rather than to Wegovy. Patients with HFpEF (heart failure with preserved ejection fraction) are not categorically excluded from the Wegovy CV pathway under the PDL language as written, but the prescribing context typically still routes them to SGLT2 (which carries an FDA HFpEF indication via empagliflozin's EMPEROR-Preserved data).

3.2 The BMI > 27 strictly-greater language

MaineCare specifies BMI strictly > 27 kg/m² (not ≥ 27). This is the narrowest BMI threshold language in the 39-state series — most states accept BMI ≥ 27 (inclusive). A patient with BMI = 27.0 kg/m² exactly would fail Maine's criteria but would pass equivalent criteria in West Virginia, Arkansas, Oklahoma, or Nebraska. In practice, BMI is reported to one decimal place, so the operational impact is small — but appeal documentation should report BMI to the highest available precision (e.g., 27.4 kg/m², not 27 kg/m²).

3.3 The “symptomatic” PAD requirement

Maine specifies symptomatic peripheral arterial disease — not just PAD with abnormal ankle-brachial index (ABI). This is more restrictive than most state Wegovy CV carve-outs, which accept asymptomatic PAD with documented ABI ≤ 0.9 or equivalent vascular imaging findings. Maine appeal documentation for PAD-based eligibility should include both objective PAD findings (ABI ≤ 0.9, peripheral revascularization, amputation) AND clinical symptom documentation (claudication symptoms, rest pain, non-healing wounds).

4. Zepbound OSA carve-out (OBSTRUCTIVE SLEEP APNEA PDL category)

Per the MaineCare PDL effective January 1, 2026 OBSTRUCTIVE SLEEP APNEA section, Zepbound is approved through PA Form #20420 for:

Zepbound for adults with a BMI ≥ 30 mg/kg² and diagnosis of moderate to severe OSA, confirmed by sleep study within the last 3 years documenting AHI ≥ 15, AND in which CPAP is ineffective (AHI > 5 during therapeutic section of sleep study) or patient is unable to tolerate CPAP for at least 90 days AND for whom lifestyle modifications have been attempted for at least 3 months with failure to achieve weight loss. Note: Not for patients with T1DM, T2DM.

Structured criteria:

1. Patient age ≥ 18 years.
2. BMI ≥ 30 kg/m².
3. Moderate-to-severe OSA confirmed by sleep study within the past 3 years documenting AHI ≥ 15.
4. CPAP failure or intolerance:
   • CPAP ineffective — AHI > 5 during the therapeutic section of the sleep study (residual AHI on CPAP), OR
   • Patient unable to tolerate CPAP for at least 90 days.
5. 3-month lifestyle modification attempt with failure to achieve weight loss.
6. NOT for patients with T1DM or T2DM — verbatim exclusion of both diabetes types.

4.1 The dual T1DM + T2DM exclusion

Maine's Zepbound OSA criteria explicitly exclude BOTH T1DM AND T2DM patients. Most state OSA carve-outs only exclude T1DM, routing T2DM patients through standard step-therapy or allowing access if the T2DM patient meets the OSA criteria. Maine's dual-diabetes exclusion routes ALL diabetic patients out of the Zepbound OSA pathway entirely — T2DM patients with moderate-to-severe OSA cannot access Zepbound for the OSA indication through MaineCare.

Operational consequence: a T2DM patient with biopsy-proven moderate-to-severe OSA who has failed CPAP would need to use Mounjaro (tirzepatide's T2D-indicated brand) for T2D and access compounded tirzepatide or pay cash for Zepbound separately if they want tirzepatide's OSA-specific weight loss effect. Mounjaro coverage requires PA Form #20420 under the Hypoglycemics-Incretin Mimetic PDL category, step 8 (non-preferred).

4.2 The 3-year sleep study window

Maine accepts sleep study documentation up to 3 years old — longer than Nebraska (24 months), Oklahoma (12 months), and Utah (requires in-lab attended polysomnography). This reduces the retesting burden for patients with longstanding OSA diagnoses but increases the diagnostic-decoupling risk where the patient's OSA severity may have changed (better or worse) since the most recent study. Patients with sleep studies older than 3 years need a fresh study before pursuing Zepbound OSA in Maine.

4.3 The CPAP-failure-OR-intolerance dual path

Maine accepts either: (a) CPAP ineffective by AHI > 5 during the therapeutic section of the sleep study (residual AHI on CPAP), OR (b) Patient unable to tolerate CPAP for at least 90 days. The 90-day intolerance window is shorter than Utah (which requires 70% PAP adherence for the full 6 months as the gate — effectively a stricter adherence floor than Maine's 90-day intolerance floor).

Documentation for intolerance path: provider note documenting the specific intolerance reason (mask discomfort, claustrophobia, skin irritation, aerophagia, nasal congestion, psychological intolerance), the 90-day attempt window, and the decision to discontinue CPAP. CPAP adherence reports from the patient's device download can support the documentation if average hours-per-night fell well below the AASM 4-hour threshold.

Documentation for ineffective path: sleep study report showing the therapeutic section with AHI > 5 despite CPAP titration to the prescribed pressure.

5. Why MaineCare has NO Wegovy MASH carve-out

Headline distinctive feature of this state: MaineCare does not have a Wegovy MASH carve-out. The GI / NASH PDL category covers ONLY Rezdiffra (resmetirol), the FDA-approved THR-β agonist for noncirrhotic MASH F2–F3 fibrosis (approved March 2024).

This is structurally significant because the FDA approved a Wegovy MASH label expansion in August 2025 (based on the ESSENCE phase 3 trial showing semaglutide 2.4 mg weekly improvement in MASH resolution without worsening fibrosis). After that label expansion, the following peer states integrated a Wegovy MASH carve-out into their Medicaid PA architectures:

• West Virginia: Wegovy MASH + Wegovy CV combined in a single PA document; F2–F3 fibrosis by biopsy or FibroScan; GI/hepatology consult.
• Arkansas: standalone Wegovy MASH PA document; F2–F3 fibrosis confirmation; GI/hepatology consult.
• Oklahoma: Wegovy MASH integrated into the four-indication carve-out architecture.
• Utah: Wegovy MASH integrated into the unified 11-part PA form; dual-modality requirement (FIB-4 + biopsy/VCTE/ELF/MRE).
• Nebraska: bifurcated standalone Wegovy MASH PA form; F2–F3 confirmation; 6-month medically-supervised weight-loss-program prerequisite.

Maine has not integrated Wegovy MASH as of January 1, 2026. The GI / NASH PDL category contains only Rezdiffra with no Wegovy MASH coverage criteria. No public DUR Board recommendation has been identified for a Wegovy MASH carve-out integration in the next PDL update cycle.

Operational consequence: a Maine patient with biopsy-proven F2–F3 noncirrhotic MASH has no documented MaineCare pathway to Wegovy. Practical options:

1. Use Rezdiffra — the only currently covered MASH-indicated therapy under the GI / NASH PDL category. Note: Rezdiffra and Wegovy have different mechanisms (THR-β vs GLP-1) and the prescribing decision depends on clinician judgment of fibrosis severity, comorbidities, and metabolic syndrome profile.
2. Cash-pay Wegovy via NovoCare — $199-$349/month depending on dose. Patients with private supplemental income or FSA/HSA can pursue this route; our cheapest semaglutide guide and GLP-1 pricing index benchmark the lowest cash prices.
3. Appeal a denial with a hepatology letter referencing the FDA Wegovy MASH label expansion (August 2025) and arguing for case-by-case coverage. Success is uncertain because the PDL has no Wegovy MASH carve-out language to anchor against.
4. Wait for MaineCare PDL update — future DUR Board reviews may integrate a Wegovy MASH carve-out as clinical evidence accumulates and as cost-utility analyses mature.

For Maine patients with both MASH and an FDA-label CV indication (BMI > 27 + MI / stroke / symptomatic PAD), the Wegovy CV carve-out is the practical access path — the MASH benefit arises as a clinical bonus of semaglutide therapy initiated for the CV indication, without separately requiring a MASH-specific PA.

6. What MaineCare does NOT cover

The MaineCare PDL effective January 1, 2026 explicitly states: “No longer covered: Phentermine, Xenical, Didrex, and Meridia. Weight loss drugs are not covered as permitted by Federal Medicaid regulations and Maine Medicaid (MaineCare) Policy.” The categorical § 80.06(A) exclusion extends to all FDA-approved chronic weight management drugs. As of January 2026:

• Wegovy for chronic weight management (non-CV indication) — NOT covered.
• Zepbound for chronic weight management (non-OSA indication) — NOT covered.
• Saxenda (liraglutide AOM) — not on PDL. Presumptively non-covered.
• Foundayo (orforglipron, oral GLP-1 AOM) — approved April 1, 2026; not yet integrated into the MaineCare PDL. Presumptively non-covered.
• Contrave (naltrexone/bupropion) — not on PDL.
• Qsymia (phentermine/topiramate) — not on PDL.
• Xenical (orlistat) — explicitly named “No longer covered” on the PDL Weight Loss page.
• Phentermine (single-agent stimulant) — explicitly named “No longer covered.”
• Wegovy MASH — no GI/NASH carve-out. Rezdiffra is the only covered MASH therapy.
• Compounded semaglutide / tirzepatide — not reimbursed under any pathway.

Cash-pay alternatives Maine residents typically use (May 2026 verified):

• NovoCare Wegovy: $199/month new-patient first 2 months; $349/month ongoing pen 0.25–2.4 mg; $399/month Wegovy HD 7.2 mg; $149/month Wegovy oral pill 1.5/4 mg.
• LillyDirect Zepbound vials: $299–$699/month depending on dose; Self Pay Journey Program $449/month for eligible 7.5–15 mg patients.
• LillyDirect Foundayo: $149/month self-pay; $25/month with commercial insurance + savings card.
• Compounded sema/tirz: $99–$199/month for compounded semaglutide; $149–$249/month for compounded tirzepatide via LegitScript-approved telehealth.

7. T2D-indicated GLP-1 pathway (INCRETIN MIMETIC PDL category)

T2D-indicated GLP-1 receptor agonists are covered under the INCRETIN MIMETIC (T2D) PDL category with PA Form #20420 for an FDA-approved diagnosis of type 2 diabetes:

• Preferred (no PA required for label-conforming T2D use): Rybelsus (oral semaglutide), Trulicity (dulaglutide).
• Non-Preferred Step 5 (PA required): Ozempic (subcutaneous semaglutide).
• Non-Preferred Step 8 (PA required): Mounjaro (tirzepatide), Victoza (liraglutide), Adlyxin (lixisenatide), Bydureon BCise (exenatide ER), Soliqua (insulin glargine + lixisenatide), Xultophy (insulin degludec + liraglutide).

The step-therapy structure routes T2D patients first through the preferred oral semaglutide (Rybelsus) or dulaglutide (Trulicity) before approving Ozempic at step 5 or Mounjaro at step 8. Off-label prescribing for chronic weight management is NOT reimbursed regardless of which T2D-indicated drug is used — a patient with T2D obtaining Ozempic for diabetes management may experience weight loss as a clinical benefit, but the prescription cannot be written for weight loss alone.

T2D-CVD overlap pathway: T2D patients with established CVD (where Ozempic carries an FDA cardiovascular indication for T2D patients) can access semaglutide via Ozempic under the T2D pathway rather than via Wegovy under the MACE carve-out (which explicitly excludes T2D patients via the “no diabetes” gate).

8. MaineCare FFS-dominant pharmacy benefit architecture

MaineCare is structurally distinctive for operating WITHOUT full-risk Medicaid managed care organizations. Maine does NOT have full-risk MCO contracts — the entire MaineCare population uses fee-for-service medical benefits and a statewide Single PDL administered by Change Healthcare Optum (Optum Rx) as PBM.

Care coordination layer (NOT MCO):

• Primary Care Case Management (PCCM): provides modest per-member-per-month coordination payments to primary care providers managing patient care; does NOT shift financial risk to the provider.
• Patient-Centered Medical Home (PCMH): similar coordination program with enhanced care-team support.
• Health Home programs: targeted at members with chronic conditions or behavioral health needs.

None of these programs operate as full-risk MCOs — they all sit on top of the underlying FFS architecture and do NOT impose their own formularies or PA processes for pharmacy. The state Single PDL applies uniformly.

Operational consequence: every MaineCare member uses the same statewide pharmacy PA process via Optum, regardless of their PCCM/PCMH/health-home enrollment status. PA submissions for Wegovy CV and Zepbound OSA go through the same Form #20420 to the same Optum helpdesk for every member.

Comparison to peer states: West Virginia also operates a single-PBM statewide architecture (Gainwell + WVU RDTP). Arkansas uses ULM College of Pharmacy / Prime Therapeutics for FFS PA processing. Nebraska uses three Heritage Health MCOs (Nebraska Total Care, UHC, Molina) but all three follow the same state Single PDL via Magellan/Prime Therapeutics. Utah uses an integrated state-administered FFS pharmacy benefit. These four states all share the single-PDL-statewide architecture but differ in whether full-risk MCOs sit above the PDL.

9. LD 480 / HP 309 — the 2025 Maine coverage-mandate bill

Representative Anne Graham (D-North Yarmouth) introduced LD 480 / HP 309 in the 132nd Maine Legislature, First Regular Session, on February 11, 2025. The bill is titled “An Act to Require Reimbursement Under the MaineCare Program for Glucagon-Like Peptide-1 Receptor Agonists Approved for the Treatment of Obesity.”

Bill text verbatim, proposed § 3174-PPP of the Maine Revised Statutes:

The department shall provide reimbursement under the MaineCare program for glucagon-like peptide-1 receptor agonists that are approved by the federal Food and Drug Administration for the treatment of obesity.

Fiscal note: approximately $42 million in FY26 and $53 million in FY27 in combined state-and-federal MaineCare program cost. The fiscal note pressure is consistent with the $42.4 million Nebraska DHHS fiscal note on LB907 ( Indefinitely Postponed April 18, 2024) and reflects the cross-state convergence on chronic-weight-management AOM coverage costs.

Disposition: Ought-Not-To-Pass Pursuant To Joint Rule 310 on March 20, 2025 — ending the bill's progression for the session without a floor vote and reaffirming MaineCare's categorical chronic-weight-management exclusion through at least the 2025–2026 legislative cycle. No successor bill has been identified in the 132nd Legislature Second Regular Session or the 133rd Legislature as of May 15, 2026.

Press context: a May 14, 2026 Lewiston Sun Journal article noted: “MaineCare, Maine's Medicaid program, would've had to grow by tens of millions of dollars to cover GLP-1s for weight loss. Even with coverage limited to diabetes and certain other conditions, MaineCare spent $42 million in the past year and demand rose 25% year-over-year.” This press framing reinforces the fiscal-pressure narrative behind the Ought-Not-To-Pass disposition.

10. Appeals pathway

MaineCare appeals run through the Maine DHHS Division of Administrative Hearings under the Maine Administrative Procedure Act and federal 42 C.F.R. § 431 Subpart E (Fair Hearings for Applicants and Recipients).

Key deadlines:

• 30 days from the notice of adverse action to file a written appeal.
• 15 days to invoke “aid paid pending” (coverage continues during the hearing if invoked within 15 days of the adverse action). This is a critical patient-protection window for ongoing prescriptions — missing the 15-day window means the patient must pay cash for any continued treatment during the appeal.

Practical denial-recovery path:

1. Contact the Change Healthcare Optum PA helpdesk (1-888-420-9711 or 1-888-445-0497; MaineHD@optum.com) to verify denial rationale. Many denials are documentation deficiencies recoverable via re-submission.
2. Re-submit PA Form #20420 with additional clinical evidence:
   • For Wegovy CV: cardiology / vascular / neurology consult note; documented MI, stroke, or symptomatic PAD; HbA1c documentation showing no diabetes; ejection fraction documentation showing no HFrEF; ABI report (if PAD is the qualifying event); BMI documented to one decimal place (e.g., 27.4 kg/m², not 27 kg/m²).
   • For Zepbound OSA: sleep study with AHI value within past 3 years; CPAP adherence report or intolerance documentation (90-day attempt window); 3-month lifestyle modification documentation; BMI ≥ 30 kg/m²; HbA1c documentation showing no T1DM or T2DM.
3. If denial stands, file written request for fair hearing within 30 days of the adverse-action notice. Contact: email farmington.dhhs@maine.gov, phone 1-855-797-4357, or local DHHS office. Mail: Commissioner, Dept. of Health and Human Services, 11 State House Station, Augusta, ME 04333.
4. Administrative hearing: Maine DHHS Division of Administrative Hearings, 109 Capitol Street, 11 State House Station, Augusta, ME 04333-0011, phone (207) 624-5350, fax (207) 287-8448, email DHHSadminhearings@maine.gov.
5. Final agency decision by the Commissioner of DHHS.
6. Judicial review in Maine Superior Court (Maine's general-jurisdiction trial court).

Appeal posture by indication:

• Wegovy CV: appeals strongest when patient meets all PDL criteria (BMI > 27, established CVD event, no diabetes / ESRD / HFrEF). Patients with BMI exactly 27.0 kg/m² should re-measure or document the trend showing previously higher BMI. Patients with HFrEF are typically ineligible — the SGLT2 pathway is the appropriate alternative.
• Zepbound OSA: appeals strongest when sleep study is within 3 years, CPAP failure/intolerance is well documented, 3-month lifestyle attempt is on record, and patient has neither T1DM nor T2DM. Diabetic patients are categorically ineligible regardless of CPAP status — this is a non-appealable PDL gate.
• Wegovy MASH: there is no current Maine pathway; appeals would need to argue for case-by-case coverage referencing the FDA Wegovy MASH label expansion (August 2025). Success is uncertain because the PDL has no Wegovy MASH carve-out language to anchor against.
• Chronic-weight-management categorical denials: cannot be overturned on appeal — the categorical exclusion is anchored to 42 U.S.C. § 1396r-8(d)(2)(A) and 10-144 C.M.R. § 80.06(A).

11. Maine vs. the 38-state taxonomy

11.1 Closest peers

• West Virginia — same posture (categorical chronic-weight-management exclusion + FDA-label CV and OSA carve-outs). Key differences: WV integrated Wegovy MASH; ME has no MASH carve-out (the headline distinctive feature). WV uses Gainwell + WVU RDTP; ME uses Optum. WV accepts BMI ≥ 27 for CV; ME requires BMI > 27. WV excludes only T1DM from Zepbound OSA; ME excludes both T1DM and T2DM.
• Arkansas — same posture + ACT 628 § 20-77-154(c) legislative ratification of the exclusion (effective January 1, 2026). AR integrated Wegovy MASH via a standalone DUR-Board-approved PA document; ME has not. AR uses ULM College of Pharmacy / Prime Therapeutics for FFS PA processing; ME uses Optum.
• Oklahoma — broader carve-out architecture (four FDA-label indications including Imcivree for monogenic obesity). OK integrated Wegovy MASH; ME has not. OK uses OU College of Pharmacy / PMC.
• Utah — legislative pilot-program chronic-weight-management coverage (sunsetting June 30, 2026) plus three indication-permanent carve-outs (Wegovy CV + Wegovy MASH + Zepbound OSA). UT's dual-modality MASH requirement (FIB-4 + biopsy/VCTE/ELF/MRE) is the most restrictive MASH gate among the integrating states; ME has not integrated MASH at all.
• Nebraska — same posture + LB907 coverage-mandate bill Indefinitely Postponed April 18, 2024 (parallel to ME's LD 480 Ought-Not-To-Pass March 20, 2025). NE integrated Wegovy MASH with a 6-month medically-supervised weight-loss-program prerequisite; ME has not integrated MASH. NE uses three Heritage Health MCOs following the state Single PDL; ME is FFS-dominant with no MCOs.

11.2 Distinctive features summary

Maine is the only state with this combination of features:

• NO Wegovy MASH carve-out — the headline distinctive feature. All five close peers (WV, AR, OK, UT, NE) integrated Wegovy MASH after the August 2025 FDA-label expansion; ME's GI/NASH PDL category covers only Rezdiffra.
• BMI strictly > 27 (not ≥ 27) for Wegovy CV — narrowest BMI threshold language in the 39-state series.
• Dual T1DM + T2DM exclusion from Zepbound OSA — most state OSA carve-outs only exclude T1DM. ME's dual-diabetes exclusion routes ALL diabetic patients out of the OSA pathway entirely.
• HFrEF (EF < 45%) explicitly excluded from Wegovy CV — reflects the structural separation between MACE-prevention (Wegovy/SELECT) and HFrEF-treatment (SGLT2/DAPA-HF/EMPEROR-Reduced).
• FFS-dominant architecture with no full-risk MCOs — rare among our state Medicaid coverage series. Most states have transitioned the bulk of their Medicaid population into MCOs.
• 3-year sleep study window for OSA — longer than NE (24 months), OK (12 months), and UT (in-lab attended PSG requirement).
• 15-day “aid paid pending” window — distinctive procedural rule giving Maine patients a tight window to invoke continued coverage during appeal.
• First state to expand Medicaid via ballot initiative — Question 2 (2017 ballot), effective January 10, 2019.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• Top compounded vs brand GLP-1 questions on Reddit, answered
• GLP-1 contraindications cheat sheet